*仅供医学专科东谈主士阅读参考赌钱赚钱软件

2024 ASCO领域有哪些新发达？

整理 |羊羊

2024年好意思国临床学会（ASCO）年会将于好意思国时分5月31日至6月4日在芝加哥巨大召开。日前，ASCO官网公布了本次会议的纲目题目。医学界特此整理乳腺癌领域的理论纲目（Oral Abstract Session）和快速理论纲目（Rapid Oral Abstract Session）标题，供读者参考与学习。

HER2+乳腺癌：单抗类药物与ADC“争夺”寰宇

■纲目号：1007

Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD)

日本多中心、立地、非劣效性III期检会（JBCRG-M06/EMERALD）成果：曲妥珠单抗+帕妥珠单抗聚合艾立布林或紫杉醇一线化疗调养HER2+、局部晚期或漂浮性乳腺癌

讲者: Toshinari Yamashita, MD, PhD | Kanagawa Cancer Center

■纲目号：1008

Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.

立地II期磋磨PATRICIA 部队 C（SOLTI-1303）的主要成果：评价哌柏西利聚合曲妥珠单抗和内分泌调养用于经治HER2+和PAM50 luminal型乳腺癌

讲者: Eva Ciruelos, MD, PhD | Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre■纲目号：1009

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

DESTINY-Breast07：在既往未经调养的HER2+ 漂浮性乳腺癌患者中进行T-DXd单药调养和T-DXd+帕妥珠单抗聚合调养的剂量扩张中期分析

讲者: Fabrice Andre, MD, PhD | Gustave Roussy, Université Paris-Saclay

■纲目号：1020

ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC)

ACE-Breast-02：ARX788（一种新式抗HER2 ADC）与拉帕替尼聚合卡培他滨调养HER2+晚期乳腺癌的瑕疵II/III期磋磨

讲者: 胡夕春熏陶 | 复旦大学从属肿瘤病院

HER2-乳腺癌：经典磋磨再更新

■纲目号：LBA1001

Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial

III期临床检会postMONARCH的主要结局：阿贝西利+氟维司群vs氟维司群单药调养既往CDK4/6扼制剂聚合内分泌调养后发达的HR+、HER2-晚期乳腺癌

讲者: Kevin Kalinsky, MD, MS | Winship Cancer Institute of Emory University■纲目号：LBA1002

Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL

立地II期Young-PEARL磋磨更重生计结局：哌柏西利+依西好意思坦聚合GnRH快乐剂vs卡培他滨调养绝经前HR+/HER2-漂浮性乳腺癌

讲者: Yeon Hee Park, MD, PhD | Samsung Medical Center, Sungkyunkwan University■纲目号：1003

First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses

III期立地检会INAVO120的荒谬分析：inavolisib/安危剂+哌柏西利+氟维司群（Inavo/Pbo+Palbo+Fulv）一线扶植内分泌调养完成时间/12个月内复发的 PIK3CA突变、HR+/HER2-局部晚期/漂浮性乳腺癌

讲者: Dejan Juric, MD | Medicine-Hematology and Medical Oncology, Massachusetts General Hospital Cancer Center■纲目号：LBA1004

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

立地II期检会SACI-IO HR+：戈沙妥珠单抗±帕博利珠单抗调养漂浮性HR+/HER2-乳腺癌

讲者: Ana Christina Garrido-Castro, MD | Dana-Farber Cancer Institute■纲目号：1005

Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202

EV-202磋磨：Enfortumab vedotin （EV）在三阴性乳腺癌（TNBC）和HR+/HER2-乳腺癌部队中的哄骗

讲者: Antonio Giordano, MD, PhD | Dana-Farber Cancer Institute■纲目号：1006

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study

TROPION-Breast01磋磨中患者呈文的结局：Dato-DXd vs化疗用于经治的不行切除或漂浮性HR+/HER2-乳腺癌

讲者: Sonia Pernas, MD, PhD | Institut Català d'Oncologia, IDIBELL, L’Hospitalet

■纲目号：1014

Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2

意大利多中心、真确宇宙、PALMARES-2磋磨的成果在HR+/HER2- aBC患者中相比哌柏西利、瑞波西利或阿贝西利一线调养的抗肿瘤疗效。

讲者: Claudio Vernieri, MD, PhD, PhD (c) | Fondazione IRCCS INT■纲目号：1015

H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC)H3B-6545在局部晚期/漂浮性ER+/HER2-女性乳腺癌患者中的哄骗

讲者: Erika P. Hamilton, MD | Sarah Cannon Research Institute

■纲目号：1017

Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer.

ER+/HER2-漂浮性乳腺癌中的种族基因组特征及靶向调养哄骗互异

讲者: Emily L Podany, MD | Washington University in St. Louis

■纲目号：511

Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

MammaPrint指数与摄取含蒽环类/不含蒽环类药死一火疗的HR+/HER2-早期乳腺癌患者的3年结局的相关性

讲者: Joyce O'Shaughnessy, MD | Baylor University Medical Center, Texas Oncology, The US Oncology Network■纲目号：512

Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trialNATALEE磋磨：淋凑趣儿阴性HR+/HER2-早期乳腺癌患者的基线特征和疗效至极

讲者: Denise A. Yardley, MD | Sarah Cannon Research Institute

其他：聚焦基因组学与肿瘤微环境

■纲目号：LBA509

Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial

I-SPY2.2磋磨成果：datopotamab deruxtecan（Dato）新扶植调养后的病理学饱和缓解 （pCR）率

讲者: Jane Lowe Meisel, MD | Winship Canter Institute of Emory University

■纲目号：513

The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer

豁免扶植内分泌调养对ER低抒发（1-10%）早期乳腺癌的影响

讲者: Grace Mei Yee Choong, MD | Mayo Clinic■纲目号：514

Oncologic outcome of response-guided axillary treatment in patients with cN1 breast cancer after primary systemic therapy.基于首次全身调养后cN1乳腺癌患者反映导向腋窝调养的肿瘤学结局

讲者: Annemiek van Hemert, MD | Antoni van Leeuwenhoek / Netherlands Cancer Institute■纲目号：515

Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trialRxPONDER磋磨：按东谈主种和种族列出的复发评分基因轴评分结局

讲者: Yara Abdou, MD | The University of North Carolina at Chapel Hill■纲目号：516

Non-basal subtype defined by FOXC1 expression as an independent predictor of capecitabine efficacy in the triple negative breast cancer GEICAM/2003-11_CIBOMA/2004-01 trialGEICAM/2003-11_CIBOMA/2004-01磋磨：以OXC1抒发界说的非基底亚型看成卡培他滨调养TNBC的疗效寥寂揣度因子

讲者: Federico Gustavo Rojo Todo, MD, PhD | Hospital Universitario Fundación Jiménez Díaz; CIBERONC-ISCCIII; GEICAM Spanish Breast Cancer Group■纲目号：517Associations of predictive biomarkers, MHC-I and MHC-II, with clinical and molecular features in a diverse breast cancer cohort在不同的乳腺癌部队中，揣度性生物标识物MHC-I和MHC-II与临床分子特征的相关性

讲者: Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center

■纲目号：1016

Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trialSONIA磋磨：内分泌调养±CDK4/6扼制剂调养的HR+晚期乳腺癌患者的贯通功能

讲者: Maryse Luijendijk, MSc | Psychosocial Research and Epidemiology, Netherlands Cancer Institute■纲目号：1018

Genomic and tumor microenvironment dynamics of brain metastases in breast cancer.

乳腺癌脑漂浮的基因组和肿瘤微环境动态

讲者: DHARMINI MANOGNA, MD | Tulane Medical University■纲目号：1019

Clinical utility of molecular imaging in newly diagnosed metastatic breast cancer.

分子影像在新会诊的漂浮性乳腺癌中的临床哄骗

讲者: Carolina Pia Schroder, MD, PhD | Department of Medical Oncology, Netherlands Cancer Institute■纲目号：1021

TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2

II期磋磨TBCRC 048扩张部队：奥拉帕利单药调养佩戴gPALB2突变或体细胞BRCA1/2突变的漂浮性乳腺癌

讲者: Nadine M. Tung, MD, FASCO | Beth Israel Deaconess Medical Center■纲目号：1022Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

BRIA-IMT（一种同种异体全细胞免疫调养）调养晚期/漂浮性乳腺癌的结局

讲者: Carmen Julia Calfa, MD | Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine

精彩资讯等你来

包袱剪辑：Sheep

*医学界勇猛其发表本色专科、可靠，但诀别本色的准确性作念出承诺；请相关各方在选择或以此看成有打算依据时另行核查。